Work Here?
About Veracyte
Industries
Biotechnology
Healthcare
Company Size
501-1,000
Company Stage
IPO
Headquarters
San Francisco, California
Founded
2008
Overview
Veracyte develops and sells advanced genomic tests for the early detection and diagnosis of various cancers. Their tests analyze genetic information from non-invasive samples like nasal swabs or tissue biopsies, providing insights into the presence and progression of cancer. This allows healthcare providers, such as hospitals and clinics, to make informed treatment decisions tailored to individual patients. Veracyte stands out from competitors by focusing on non-invasive testing methods and continuously investing in research to expand their product offerings. Their goal is to improve cancer diagnosis accuracy and patient outcomes, as seen in their recent products like the Decipher Prostate genomic classifier and a nasal swab test for lung cancer risk assessment.
Simplify's Take
What believers are saying
- Increased AI adoption enhances the precision of Veracyte's genomic tests.
- Liquid biopsy technology expands Veracyte's market reach with non-invasive alternatives.
- Global precision medicine initiatives drive demand for Veracyte's advanced diagnostic tools.
What critics are saying
- AI-based tests may show bias due to non-diverse initial development.
- ClearLab's 2026 launch may face market penetration and regulatory challenges.
- Continuous R&D reliance may strain finances if new tests lack validation.
What makes Veracyte unique
- Veracyte specializes in non-invasive genomic tests for early cancer detection.
- The Decipher Prostate genomic classifier aids in prostate cancer prognosis.
- Veracyte's nasal swab test improves early lung cancer risk assessment.
Help us improve and share your feedback! Did you find this helpful?
Funding
Total Funding
$1148.4M
Above
Industry Average
Funded Over
6 Rounds
Kleiner PerkinsBenefits
Performance Bonus
Stock Options
Remote Work Options
Growth & Insights and Company News
6 month growth
↑ 0%1 year growth
↑ 0%2 year growth
↑ 0%Proficio Capital Partners LLC invests $1.18 million in Veracyte, Inc. (NASDAQ:VCYT).
Veracyte (VCYT) announced multiple abstract presentations at the 40th Annual European Association of Urology Congress (EAU25) in Madrid, Spain, showcasing the clinical performance and utility of its Decipher tests for prostate and bladder cancer.
Veracyte, Inc. announced that new data presented at the 2025 ASCO Genitourinary Cancers Symposium (ASCO GU) demonstrate the performance and clinical utility of its Decipher Prostate and Decipher Bladder tests to help guide treatment for patients with prostate and bladder cancer.
HighTower Advisors LLC makes new investment in Veracyte, Inc. (NASDAQ:VCYT).
That's why Veracyte is testing their Decipher Prostate Genomic Classifier, an AI-based transcriptome genetic test that was developed using primarily White American males, on Black African American males to see if it offers clinicians an improvement over clinical factors alone in guiding prostate cancer treatment decisions.
Veracyte is Hiring for 15 Jobs on Simplify!
Find jobs on Simplify and start your career today
People Also Viewed
Discover companies similar to Veracyte
About Veracyte
Industries
Biotechnology
Healthcare
Company Size
501-1,000
Company Stage
IPO
Headquarters
San Francisco, California
Founded
2008
Veracyte is Hiring for 15 Jobs on Simplify!
Find jobs on Simplify and start your career today
People Also Viewed
Discover companies similar to Veracyte